Invention Grant
- Patent Title: Combinations of proteasome inhibitors and cyclic peptides
-
Application No.: US15523188Application Date: 2015-10-27
-
Publication No.: US10166269B2Publication Date: 2019-01-01
- Inventor: John Bernard March , Ewan McIntosh Clark
- Applicant: BIG DNA LTD
- Applicant Address: GB Roslin, Midlothian
- Assignee: BIG DNA LTD
- Current Assignee: BIG DNA LTD
- Current Assignee Address: GB Roslin, Midlothian
- Agency: Morgan, Lewis & Bockius LLP
- Priority: GB1419311.4 20141030; GB1500681.0 20150115; GB1506673.1 20150420
- International Application: PCT/GB2015/053215 WO 20151027
- International Announcement: WO2016/067010 WO 20160506
- Main IPC: A61K38/12
- IPC: A61K38/12 ; A61K38/06 ; A61K31/407 ; A61K38/07 ; A61K38/05 ; A61K38/00 ; A61K31/69 ; A61K45/06 ; A61K31/4015
Abstract:
The present invention relates to a combination comprising a proteasome inhibitor and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety. In particular, the present invention relates to a combination comprising a proteasome inhibitor selected from the group consisting of: a boronate, an epoxyketone, a peptide aldehyde and a β-lactone protease inhibitor; and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety. More particularly, the present invention relates to a combination comprising a proteasome inhibitor selected from the group consisting of: bortezomib, delanzomib, ixazomib, carfilzomib, oprozomib, MG132 and marizomib; and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety.
Public/Granted literature
- US10328116B2 Combinations of proteasome inhibitors and cyclic peptides Public/Granted day:2019-06-25
Information query
IPC分类:
